Flugen, Inc.

Company Information
Address 597 SCIENCE DR STE 10
MADISON, WI, 53711-1062

http://www.flugen.com

Information

DUNS: 827404208

# of Employees: 7


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of a novel highly effective influenza vaccine

    Amount: $1,489,965.00

    Seasonal influenzafluvirusan NIAID category C priority pathogencauses widespread infectionresulting in at leastmillion cases of severe illness anddeaths worldwideWhile annual vaccination is recommende ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  2. Restimulating memory T cell responses in elderly by a novel, live influenza vaccine

    Amount: $1,833,981.00

    Respiratory infections with influenza viruses cause severe morbidity and mortality in humans and animals worldwideImportantlyin humansthe majority of morbidity and mortality following flu infection is ...

    STTRPhase II2017Department of Health and Human Services
  3. Restimulating memory T cell responses in elderly by a novel, live influenza vaccine

    Amount: $224,997.00

    DESCRIPTION provided by applicant Respiratory infections with influenza viruses cause severe morbidity and mortality in humans and animals worldwide Importantly in humans the majority of morbid ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Development of a novel highly effective influenza vaccine

    Amount: $600,000.00

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
  5. A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells

    Amount: $220,126.00

    DESCRIPTION (provided by applicant): A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells. In 2009, the traditional means of vaccine manufacturing for the H1N1 influenza pandemic ...

    SBIRPhase I2012Department of Health and Human Services
US Flag An Official Website of the United States Government